- Home
- WNEB vs PBYI Comparison
WNEB vs PBYI Comparison
Compare WNEB & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- PBYI
- Stock Information
- Founded
- WNEB 1853
- PBYI 2010
- Country
- WNEB United States
- PBYI United States
- Employees
- WNEB N/A
- PBYI N/A
- Industry
- WNEB Savings Institutions
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- PBYI Health Care
- Exchange
- WNEB Nasdaq
- PBYI Nasdaq
- Market Cap
- WNEB 195.7M
- PBYI 171.7M
- IPO Year
- WNEB N/A
- PBYI N/A
- Fundamental
- Price
- WNEB $11.44
- PBYI $4.76
- Analyst Decision
- WNEB Buy
- PBYI Strong Buy
- Analyst Count
- WNEB 2
- PBYI 1
- Target Price
- WNEB $11.00
- PBYI $7.00
- AVG Volume (30 Days)
- WNEB 97.2K
- PBYI 559.4K
- Earning Date
- WNEB 07-22-2025
- PBYI 08-07-2025
- Dividend Yield
- WNEB 2.53%
- PBYI N/A
- EPS Growth
- WNEB N/A
- PBYI 434.29
- EPS
- WNEB 0.59
- PBYI 0.97
- Revenue
- WNEB $76,036,000.00
- PBYI $238,062,000.00
- Revenue This Year
- WNEB N/A
- PBYI N/A
- Revenue Next Year
- WNEB $7.36
- PBYI N/A
- P/E Ratio
- WNEB $18.78
- PBYI $4.98
- Revenue Growth
- WNEB 2.15
- PBYI 8.63
- 52 Week Low
- WNEB $7.42
- PBYI $2.23
- 52 Week High
- WNEB $11.68
- PBYI $5.05
- Technical
- Relative Strength Index (RSI)
- WNEB 65.12
- PBYI 83.07
- Support Level
- WNEB $10.94
- PBYI $3.05
- Resistance Level
- WNEB $11.41
- PBYI $5.06
- Average True Range (ATR)
- WNEB 0.29
- PBYI 0.26
- MACD
- WNEB -0.01
- PBYI 0.17
- Stochastic Oscillator
- WNEB 90.24
- PBYI 89.16
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.